Nice — I pulled together a compact, source-backed reference for the Genomics market with company values (2024 or closest reported year) and short, actionable points for each section you requested.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Genomics market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Genomics market.

Read complete report at: https://www.thebrainyinsights.com/report/genomics-market-13620

Top companies & 2024 values (reported / closest available)
Where companies report large diversified revenues (e.g., Thermo Fisher, Roche, Danaher), I show full-company 2024 revenues and note their genomics / life-science positions. For specialist genomics firms I show their direct 2024 revenues.

Thermo Fisher Scientific — Revenue: $42.88 billion (FY2024). Major supplier of sequencing consumables, sample prep, instruments and genomics workflows.

Roche Group — Group sales: CHF 60.495 billion (2024); Diagnostics division (important for clinical genomics) Diagnostics sales: CHF 14.324 billion (2024).

Danaher Corporation — Revenue: $23.9 billion (2024); large Life Sciences & Diagnostics footprint (molecular, automation, genomics tools).

Illumina, Inc. — Core Illumina revenue: ~$4.3 billion (FY2024) (sequencing instruments, consumables; note regulatory/market headwinds in China in 2025).

Agilent Technologies — Revenue: ≈ $6.5 billion (FY2024); significant genomics / sample-prep / analysis product lines.

10x Genomics — Revenue: $610.8 million (FY2024) — single-cell & spatial biology platforms (instruments + consumables).

BGI Genomics — Revenue: RMB 3.87 billion (~US$531M) in 2024 (Chinese integrated genomics provider; drop vs 2023).

Oxford Nanopore Technologies — Revenue: £183.2 million (FY2024) (long-read nanopore sequencing systems and consumables).

Pacific Biosciences (PacBio) — Revenue: ≈ $154 million (FY2024) (high-accuracy long-read systems — Revio).

(Note: many large diagnostics/Life-Science companies (e.g., Thermo Fisher, Danaher, Roche, Agilent) do not report “genomics only” top-line; I included their FY2024 company revenues and referenced their genomics or molecular diagnostics businesses. Specialist genomics vendors (Illumina, 10x, Oxford Nanopore, PacBio, BGI) report genomics-specific revenues above.)

Recent development (high-impact items)
Market size & growth: industry reports estimate the global genomics market (NGS, instruments, consumables, bioinformatics, services) in the tens of billions — many forecasts show a strong mid-teens CAGR through the late 2020s (examples: Mordor/GrandView and others).

Platform shift: short-read + long-read + single-cell / spatial — adoption of long-read (Oxford Nanopore, PacBio Revio) and single-cell / spatial platforms (10x Genomics) is accelerating new use cases.

Clinical translation & diagnostics expansion — greater integration of genomics into oncology, rare disease diagnostics, and population sequencing programs (governments / large biobanks) is pushing demand for instruments and consumables.

Supply / regulatory shocks: Illumina faced China import restrictions (impacting FY2025 outlook) and vendors are navigating funding volatility (NIH/grant changes) affecting instrument purchases.

Drivers
Expanding clinical applications — oncology (liquid biopsy, companion diagnostics), rare disease testing, neonatal screening and infectious disease genomics.

Falling per-base sequencing costs + higher throughput instruments — increases affordability for large projects (biobanks, population sequencing).

Rise of single-cell, spatial, and long-read workflows — opens new biological insights and premium consumables demand (higher ASP).

Growing bioinformatics & cloud analytics — recurring software and services revenue beside hardware/consumables.

Restraints
Capital intensity and budget cycles — instrument purchases are lumpy and sensitive to research funding (NIH/academic grants), macro headwinds and tariffs.

Regulatory and trade risks — export/import restrictions or tariffs (example: Illumina/China issue) can materially impact company revenues.

Fragmented product economics — many vendors sell instruments at low margins and rely on consumables pull-through; competition pressures ASPs.

Regional segmentation (high level)
North America (largest market by revenue/innovation) — high research funding, clinical genomics adoption, pharma/biotech customers.

Asia-Pacific (fastest growth) — large population genomics programs (China, India, Middle East initiatives), strong manufacturing (BGI, many reagent OEMs).

Europe — strong diagnostics/regulatory frameworks, growing applied markets (public health sequencing, pathogen genomics).

Rest of world (LATAM, MEA) — opportunistic growth in public health/genomics-enabled projects but constrained by budgets and local infrastructure.

Emerging trends
Population sequencing & national biobanks — sustained demand for high-throughput sequencing and consumables.

Single-cell & spatial scaling — more scalable chemistries and instruments (10x and competitors) enabling translational research.

Long-read adoption improving (ONT, PacBio) — more high-value applications (structural variant detection, full-length transcriptomics).

Recurring revenue models — cloud analytics, subscription software, and consumables pull-through to improve margins.

Top use cases
Clinical diagnostics (oncology panels, non-invasive prenatal testing, rare disease).

Research & drug discovery (genomics + single-cell to guide target ID / biomarkers).

Population genomics / biobanks (large-scale sequencing programs).

Infectious disease & public health surveillance (pathogen sequencing, outbreak tracing).

Major challenges
Funding volatility (academic & government) — directly affects instrument and consumable purchasing cycles.

Competition & margin pressure — many vendors competing on consumables and instrument ecosystems.

Regulatory/trade uncertainty — export bans, tariffs or local procurement rules can disrupt market access.

Attractive opportunities
End-to-end clinical solutions — labs + instruments + CLIA/CE-IVD workflows for diagnostics (higher stickiness).

Cloud + AI for genomics interpretation — recurring revenue, value-add, and differentiation vs pure hardware vendors.

Applied markets beyond research — agriculture, forensics, environmental genomics, and industrial biotech.

Key factors of market expansion
Research funding & healthcare reimbursement — stable/expanding grants and diagnostic reimbursement unlock purchases.

Technology improvements (throughput, cost per genome, accuracy) — drive adoption across more use cases.

Commercial models that convert hardware buyers into long-term consumable/software customers (pull-through economics).

Regulatory clarity for clinical use — clear approval pathways for genomic diagnostics accelerate uptake.

Selected sources (representative / to follow up)
Grand View Research — Genomics market report (market sizing & trends).

Mordor Intelligence — Genomics market overview & CAGR estimates.

Illumina FY2024 results; company press releases (Illumina core revenue ~ $4.3B, 2024).

Thermo Fisher Scientific FY2024 annual report (revenue $42.88B).

Roche Annual Report 2024 (Group sales CHF 60.495B; Diagnostics CHF 14.324B).

10x Genomics FY2024 results (revenue $610.8M).

Oxford Nanopore FY2024 revenue £183.2M; PacBio FY2024 revenue ≈ $154M.

BGI Genomics 2024 annual report coverage (RMB 3.87B).

Would you like any of these next (I can create one now):

A spreadsheet (CSV/XLSX) listing the companies + 2024 revenues + source links and currencies standardized.

A one-page PowerPoint summarizing the market and top company numbers for stakeholders.

A deep dive on a single company (Illumina / Thermo Fisher / 10x / Oxford Nanopore) with product breakdown, revenues by segment, and recent news.

Say “1”, “2”, or “3 (company name)” and I’ll generate it immediately.